OrbiMed’s Sarepta Therapeutics SRPT Stock Holding History

OrbiMed’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-50,000	Closed	-$6.24M	–	138
2024 Q3	$6.24M	Hold	50,000	–	–	0.11%	90
2024 Q2	$7.9M	Buy	+50,000	New	+$6.42M	0.16%	81
2023 Q2	–	Sell	-75,000	Closed	-$10.3M	–	135
2023 Q1	$10.3M	Buy	+75,000	New	+$9.73M	0.2%	87
2021 Q1	–	Sell	-50,000	Closed	-$8.53M	–	178
2020 Q4	$8.53M	Buy	+50,000	New	+$7.41M	0.07%	125
2019 Q4	–	Sell	-50,000	Closed	-$3.77M	–	145
2019 Q3	$3.77M	Buy	+50,000	New	+$5.9M	0.07%	99
2018 Q2	–	Sell	-50,000	Closed	-$3.71M	–	153
2018 Q1	$3.71M	Hold	50,000	–	–	0.05%	123
2017 Q4	$2.78M	Sell	50,000 -100,000	-67%	-$5.3M	0.04%	121
2017 Q3	$6.8M	Buy	+150,000	New	+$5.99M	0.07%	116

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

OrbiMed's SRPT Position: Q1 2025 in Review

OrbiMed sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 963,400 shares — an estimated $117M sold.

OrbiMed first reported a position in SRPT in Q3 2016 and held it in 31 quarters. The position peaked at $138M in Q3 2018. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

OrbiMed reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
OrbiMed sold 963,400 Sarepta Therapeutics shares in Q1 2025, an estimated $117M.
OrbiMed first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 31 quarters.
OrbiMed's Sarepta Therapeutics position peaked at $138M in Q3 2018.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on OrbiMed's 13F filing for Q1 2025, filed 15 May 2025.